Summary
“Erythropoietin”
is a glycoprotein hormone synthesized in the bone marrow that controls and
regulates the mechanism of erythropoiesis (production of red blood cells). These
erythropoietin (EPO) drugs are used for treatment of chemotherapy-induced
anemia; anemia is a common side-effect occurring due to chemotherapy of End
Stage Renal Diseases (ESRD), cancer and HIV. Improved recombinant DNA technology
has led to development of synthetic forms of erythropoietin such as epoetin alfa,
epoetin beta, darbepoetin alfa, epoetin omega, and epoetin delta among the
others. The global EPO drugs market is thus driven by increasing number of
patients suffering from anemic condition induced due to cancer, HIV and ESRD
treatment; favorable reimbursements and increasing commercialization of EPO
biosimilars. The global EPO drugs market would reach $11.9 billion by 2020,
registering CAGR of 9.7% during 2014-2020.
Amongst all synthetic erythropoietin products, Epoetin alfa and its advance
version, Darbepoetin alfa, are the most popular drugs. Epoetin alfa and
Darbepoetin alfa collectively accounted for ~80% of total EPO drugs market
revenue. Amgen Inc. was first company to innovate Epoetin alfa and Darbepoetin
alfa that are branded/patented as Epogen and Aranesp respectively. However,
expiration of Amgens patent for Epogen has aided manufacturers of biosimilars to
enter the EPO drugs market. Availability of numerous biosimilars has rendered
low-cost option to the patients, therefore increased adoption rates for EPO
drugs particularly in the developing regions.
Based on the applications, the global EPO drugs market is segmented into anemia
associated with End Stage Renal Diseases (ESRD), cancer chemotherapy and,
antiretroviral treatment (ART). Current research is focused toward expanding the
applications of EPO drugs in other disease conditions such as neural diseases
and wound healing.
Global EPO drugs market is segmented based on geography into North America,
Europe, Asia Pacific and LAMEA. Europe is the leading geographical market owing
to favorable reimbursement policies and less stringent and speedy regulatory
approvals for EPO drugs.
Key companies profiled in the report are, Amgen Inc., Johnson & Johnson, Hospira
Inc., Roche, LG Life Sciences Ltd., Biocon, Intas Pharmaceuticals, Teva
Pharmaceutical Industries Ltd., Ranbaxy Laboratories Ltd., and Celltrion, Inc.
KEY BENEFITS
An in-depth analysis of current research and clinical developments within EPO
drugs market is provided with key market dynamic factors that helps in
understanding the behavior of market
The report provides the quantitative analysis of the current market and
estimations through 2013-2020 that assists in identifying the prevailing market
opportunities to capitalize on
Extensive analysis of the market is conducted by closely following key product
positioning and monitoring the top contenders within the market framework
Comprehensive analysis of all geographic regions are provided that helps in
determining the prevailing opportunities in these geographies
Key market players within the EPO drugs market are profiled in the report and
their strategies are analyzed thoroughly, which helps in understanding
competitive outlook of global EPO drugs market
MARKET SEGMENTATION
The global EPO drugs market is segmented based on products, applications and
geography.
MARKET BY PRODUCT TYPES
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
MARKET BY APPLICATIONS
Anemia (Cancer and HIV treatment)
Kidney Disorders (ESRD and Dialysis)
Others (Neural Disease and Wound healing)
MARKET BY GEOGRAPHY
North America
Europe
Asia-Pacific
LAMEA
You can order full Report with TOC and Sample page visit
For more Market research Report:
http://www.aarkstore.com/market-research-reports-categories.htmlAbout Aarkstore.Com
Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on Market Research Reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.
Contact Details:
Aarkstore Enterprise
Phone: +91 9987295242 / 022-27564953
Email: enquiry@aarkstore.com
Our Website: http://www.aarkstore.com
Our Blog : http://www.aarkstore.com/blog/
Latest News : http://www.aarkstore.com/news
conference: http://conference.aarkstore.com/
Phone: +91 9987295242 / 022-27564953
Email: enquiry@aarkstore.com
Our Website: http://www.aarkstore.com
Our Blog : http://www.aarkstore.com/blog/
Latest News : http://www.aarkstore.com/news
conference: http://conference.aarkstore.com/
No comments:
Post a Comment